G1 THERAPEUTICS (NASDAQ:GTHX) Director Fredric N. Eshelman acquired 250,000 shares of the firm’s stock in a transaction on Monday, November 13th. The shares were bought at an average cost of $19.73 per share, for a total transaction of $4,932,500.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

G1 THERAPEUTICS (NASDAQ GTHX) traded up $1.60 during trading hours on Friday, hitting $20.75. 665,200 shares of the stock were exchanged, compared to its average volume of 94,664. G1 THERAPEUTICS has a 52 week low of $12.04 and a 52 week high of $28.67.

ILLEGAL ACTIVITY WARNING: “G1 THERAPEUTICS (GTHX) Director Fredric N. Eshelman Purchases 250,000 Shares of Stock” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/11/17/g1-therapeutics-gthx-director-fredric-n-eshelman-purchases-250000-shares-of-stock.html.

Several large investors have recently bought and sold shares of the company. Alps Advisors Inc. raised its stake in shares of G1 THERAPEUTICS by 9.1% in the third quarter. Alps Advisors Inc. now owns 27,766 shares of the company’s stock valued at $691,000 after acquiring an additional 2,317 shares during the last quarter. Chartwell Investment Partners LLC raised its stake in shares of G1 THERAPEUTICS by 5.0% in the third quarter. Chartwell Investment Partners LLC now owns 92,558 shares of the company’s stock valued at $2,303,000 after acquiring an additional 4,388 shares during the last quarter. American International Group Inc. bought a new position in shares of G1 THERAPEUTICS in the third quarter valued at approximately $130,000. California State Teachers Retirement System bought a new position in shares of G1 THERAPEUTICS in the third quarter valued at approximately $319,000. Finally, Schwab Charles Investment Management Inc. bought a new position in shares of G1 THERAPEUTICS in the third quarter valued at approximately $364,000. Institutional investors own 35.28% of the company’s stock.

A number of equities research analysts have weighed in on the company. Zacks Investment Research downgraded G1 THERAPEUTICS from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Cowen and Company reiterated a “buy” rating on shares of G1 THERAPEUTICS in a research note on Wednesday, November 8th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $29.75.

G1 THERAPEUTICS Company Profile

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Receive News & Stock Ratings for G1 THERAPEUTICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 THERAPEUTICS and related stocks with our FREE daily email newsletter.